NLRP3炎症小体的活化机制及其抑制剂在关节炎症性疾病中的研究进展  

Research Progress in Activation Mechanism of Inflammasome NLRP3 and Its Inhibitors in Joint Inflammatory Diseases

作　　者：闫洪领[1] 周彩玲[1] 张玉超[1] 路巍[1] YAN Hongling;ZHOU Cailing;ZHANG Yuchao;LU Wei(Department of Endocrinology,Qingdao Hospital(Qingdao Municipal Hospital),University of Health and Rehabilitation Sciences,Qingdao 266003,China)

机构地区：[1]康复大学青岛医院(青岛市市立医院)内分泌科,山东青岛266003

出　　处：《医学综述》2023年第9期1686-1691,共6页Medical Recapitulate

基　　金：山东省医药卫生科技发展计划项目(202103060651)。

摘　　要：核苷酸结合寡聚化结构域样受体蛋白3(NLRP3)是炎症反应的核心,其异常活化后可通过参与调节胱天蛋白酶1(caspase-1)的活化,促进白细胞介素(IL)-1β前体和IL-18前体的成熟和分泌,还可调节caspase-1依赖的细胞凋亡,诱导细胞在炎症及应激条件下死亡,与多种疾病密切相关。NLRP3在关节炎症性疾病中表达异常,部分NLRP3炎症小体抑制剂对关节炎症性疾病的治疗已进入Ⅱ~Ⅲ期临床试验阶段。深入研究NLRP3炎症小体的活化机制及其抑制剂在关节炎症性疾病中的作用,可为关节炎症性疾病的治疗提供新思路。Nucleotide-binding oligomerization domain-like receptor protein 3(NLRP3)is the core of inflammatory response.Abnormal activation of NLRP3 can promote the maturation and secretion of cytokines pro-interleukin(IL)-1βand pro-IL-18 by participating in the regulation of caspase-1 activation.It can also regulate caspase-1-dependent apoptosis and induce cell death under inflammatory and stress conditions,which is closely related to a variety of diseases.NLRP3 is abnormally expressed in joint inflammatory diseases,and some NLRP3 inflammasome inhibitors have entered stageⅡ-Ⅲclinical trials for the treatment of joint inflammation.Further study on the activation mechanism of NLRP3 inflammasome and the role of its inhibitors in joint inflammatory diseases can provide new ideas for the treatment of joint inflammatory diseases.

关 键 词：关节炎症性疾病 核苷酸结合寡聚化结构域样受体蛋白3 抑制剂 炎症反应 

分 类 号：R392.9[医药卫生—免疫学]